Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has The Antiobesity Market Size Shifted, And What Is the Outlook Through 2034?
The market size for antiobesity has seen a swift escalation in the past years. It is projected to expand from $3.74 billion in 2024 to reach $4.15 billion in 2025, witnessing a compound annual growth rate (CAGR) of 11.1%. The significant expansion during the historical period is closely associated with the rise in obesity rates, improved awareness and education, lifestyle transformations, and governmental interventions.
How Much Will the Antiobesity Market Be Worth in 2029?
Expectations are high for the antiobesity market to experience significant expansion in the coming years, with projections pointing to a growth to $6.08 billion by 2029. This reflects a compound annual growth rate (CAGR) of 10.0%. The anticipated growth over the forecast period is largely due to factors such as market expansion and globalization. Key trends to watch during this time span include increased emphasis on research and development, a patient-based approach, insurance coverage, advanced technology, the incursion of digital health and telemedicine, groundbreaking drug therapies, advancements in bariatic surgery, OTC solutions, behavioral strategies, and the rise of nutritional and weight control applications.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3403&type=smp
Which is the Largest Company in the Antiobesity Market?
Major companies operating in the antiobesity market include F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.
What Are the Main Market Drivers in the Antiobesity Industry?
The worldwide concern for public health is increasingly focusing on obesity. The Global prevalence of obesity is on an upward trajectory with each passing year. The World Obesity Atlas, an organization based out of the UK, reported in May 2022 that they predict over 1 billion individuals will be dealing with obesity globally by 2030. This projected increase is due to factors such as the rise in the consumption of processed and unhealthy food, insufficient physical exercise, and deficiency in the awareness of obesity-related risks. Consequently, there will likely be a growing demand for anti-obesity medications, providing a boost for the market’s growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=3403&type=smp
How Is the Antiobesity Market Segments Structured?
The antiobesity market covered in this report is segmented –
1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs
2) By Type: Prescription Drugs (Rx), OTC Drugs
3) By Medication: Monotherapies, Polytherapies
Subsegments:
1) By Peripherally Acting Anti-Obesity Drugs: Orlistat, Lorcaserin
2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide
What Strategic Trends Are Transforming the Antiobesity Market?
In the anti-obesity drug market, leading firms are focusing on new product innovation to better service their customers, with a particular emphasis on drugs like Mounjaro (tirzepatide). This drug is specifically designed for the treatment of adults battling with obesity or overweight issues, along with associated health complications. In a recent development, Eli Lilly and Company, an American pharmaceutical giant, introduced Mounjaro (tirzepatide) in October 2022 after securing approval from the US Food and Drug Administration (FDA) under their fast track designation protocol. Mounjaro (tirzepatide) is an injectable anti-obesity drug aimed at assisting individuals dealing with obesity in meeting their weight loss objectives. It’s also recommended for adults diagnosed with type 2 diabetes and is used alongside diet and exercise to regulate blood sugar (glucose) levels.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report
Which Global Regions Offer the Highest Growth in the Antiobesity Market?
North America was the largest region in the anti-obesity market in 2023. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3403
This Report Delivers Insight On:
1. How big is the antiobesity market, and how is it changing globally?
2. Who are the major companies in the antiobesity market, and how are they performing?
3. What are the key opportunities and risks in the antiobesity market right now?
4. Which products or customer segments are growing the most in the antiobesity market?
5. What factors are helping or slowing down the growth of the antiobesity market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
